Nano Science and Technology Institute

Nano-Pharmceutical Company Enters Into Research Agreement with Vaccine Branch of National Cancer Institute

Nanotherapeutics, Inc. recently announced it has a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI). Nanotherapeutics plans to create HIV peptide oral vaccine nanoparticles using its exclusive technology. Mr. James D. Talton, Ph.D., Co-Founder and President of Nanotherapeutics, is the company’s principal investigator for the project. The collaboration with the NCI will involve the company’s proprietary nanoparticle delivery system to improve immune response.

↑ Back to Nano World Breaking News™

↑ Back to Nano World News™

Nano World News™ Issue Archive:

RSS feed RSS feed

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map